BIOCRYST PHARMACEUTICALS, INC. (BCRX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2017-12-31..
Gross margin
Overview →Financial period ending 2017-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2017-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 25.19M USD | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2017-12-31 | (m) | $25.19M | (m) | (m) |
| 2017-09-30 | (m) | $30.28M | (m) | (m) |
| 2017-06-30 | (m) | $29.28M | (m) | (m) |
| 2017-03-31 | (m) | $30.97M | (m) | (m) |
| 2016-12-31 | (m) | $26.35M | (m) | (m) |
| 2016-09-30 | (m) | $21.97M | (m) | (m) |
| 2016-06-30 | (m) | $25.20M | (m) | (m) |
| 2016-03-31 | (m) | $46.25M | (m) | (m) |
| 2015-12-31 | (m) | $48.26M | (m) | (m) |
| 2015-09-30 | (m) | $49.10M | (m) | (m) |
| 2015-06-30 | (m) | $41.35M | (m) | (m) |
| 2015-03-31 | (m) | $16.98M | (m) | (m) |
| 2014-12-31 | (m) | $13.61M | (m) | (m) |
| 2014-09-30 | (m) | $18.73M | (m) | (m) |
| 2014-06-30 | (m) | $17.88M | (m) | (m) |
| 2014-03-31 | (m) | $17.23M | (m) | (m) |
| 2013-12-31 | (m) | $17.33M | (m) | (m) |
| 2013-09-30 | (m) | $10.87M | (m) | (m) |
| 2013-06-30 | (m) | $14.24M | (m) | (m) |
| 2013-03-31 | (m) | $17.63M | (m) | (m) |
| 2012-12-31 | (m) | $26.29M | (m) | (m) |
| 2012-09-30 | (m) | $27.42M | (m) | (m) |
| 2012-06-30 | (m) | $26.90M | (m) | (m) |
| 2012-03-31 | (m) | $26.43M | (m) | (m) |
| 2011-12-31 | (m) | $19.64M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $62.38M | $86.00K | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $74.59M | $4.54M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |